Pulse Biosciences (PLSE) Registration Filing summary

Company overview and business model

• Focuses on Nano-pulse Stimulation (NPS) technology, a nonthermal ablation platform for targeted cell treatment across multiple medical specialties, including cardiology and soft tissue ablation.

• Developed the nPulse System, commercialized for benign skin lesions, with ongoing preclinical studies in cardiology, gastroenterology, gynecology, and otolaryngology.

• Shifted primary efforts in 2022 to atrial fibrillation and select high-impact markets based on preclinical results and market potential.

Financial performance and metrics

• As of December 31, 2025, 67,839,689 shares of common stock were issued and outstanding, held by 11 stockholders of record.

• The last reported sales price of common stock on February 18, 2026, was $25.46 per share.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, with specifics to be detailed in each prospectus supplement.

• Proceeds may be temporarily invested prior to use.